Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ADXN NYSE:ATNM NASDAQ:BGM NASDAQ:TAOX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$5.87-0.4%$6.30$5.41▼$12.05$7.25M1.52,057 shs249 shsATNMActinium Pharmaceuticals$0.86-3.5%$1.03$0.86▼$1.86$27.96M-0.02144,143 shs113,153 shsBGMBGM Group$0.29-0.3%$0.33$0.25▼$11.80$28.26M1.78406,872 shs46,044 shsTAOXSynaptogenix$3.29-10.4%$3.88$3.22▼$10.00$27.42M1.4286,513 shs130,224 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-0.19%+0.51%-2.25%-16.21%-29.93%ATNMActinium Pharmaceuticals-3.48%-6.71%-14.85%-32.81%-54.01%BGMBGM Group-0.34%+2.84%-15.09%-13.00%-97.06%TAOXSynaptogenix-10.35%-4.91%-2.95%-36.61%+328,999,900.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeADXNAddex Therapeutics$5.87-0.4%$6.30$5.41▼$12.05$7.25M1.52,057 shs249 shsATNMActinium Pharmaceuticals$0.86-3.5%$1.03$0.86▼$1.86$27.96M-0.02144,143 shs113,153 shsBGMBGM Group$0.29-0.3%$0.33$0.25▼$11.80$28.26M1.78406,872 shs46,044 shsTAOXSynaptogenix$3.29-10.4%$3.88$3.22▼$10.00$27.42M1.4286,513 shs130,224 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceADXNAddex Therapeutics-0.19%+0.51%-2.25%-16.21%-29.93%ATNMActinium Pharmaceuticals-3.48%-6.71%-14.85%-32.81%-54.01%BGMBGM Group-0.34%+2.84%-15.09%-13.00%-97.06%TAOXSynaptogenix-10.35%-4.91%-2.95%-36.61%+328,999,900.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceADXNAddex Therapeutics 1.00SellN/AN/AATNMActinium Pharmaceuticals 3.00Buy$5.00481.40% UpsideBGMBGM Group 1.00SellN/AN/ATAOXSynaptogenix 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest ADXN, ATNM, TAOX, and BGM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/17/2026TAOXSynaptogenix Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/6/2026ADXNAddex Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (E+)(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookADXNAddex Therapeutics$29.97K241.08N/AN/A$4.67 per share1.26ATNMActinium Pharmaceuticals$90K299.81N/AN/A$1.31 per share0.66BGMBGM Group$37.92M0.74N/AN/A$7.34 per share0.04TAOXSynaptogenix$300K81.92N/AN/A$2.83 per share1.16Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateADXNAddex Therapeutics-$8.12M-$5.94N/AN/AN/AN/A-134.76%-106.00%8/24/2026 (Estimated)ATNMActinium Pharmaceuticals-$48.82M-$0.75N/AN/AN/AN/A-100.85%-47.89%N/ABGMBGM Group-$1.44MN/AN/AN/AN/AN/AN/AN/AN/ATAOXSynaptogenix-$28.74M-$13.28N/AN/AN/AN/A-163.40%-133.47%N/ALatest ADXN, ATNM, TAOX, and BGM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2026Q1 2026TAOXSynaptogenixN/A$0.43N/A$0.43N/A$5.96 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthADXNAddex TherapeuticsN/AN/AN/AN/AN/AATNMActinium PharmaceuticalsN/AN/AN/AN/AN/ABGMBGM GroupN/AN/AN/AN/AN/ATAOXSynaptogenixN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioADXNAddex TherapeuticsN/A0.970.97ATNMActinium PharmaceuticalsN/A10.2510.25BGMBGM GroupN/AN/AN/ATAOXSynaptogenixN/A27.3927.39Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipADXNAddex Therapeutics16.14%ATNMActinium Pharmaceuticals27.50%BGMBGM GroupN/ATAOXSynaptogenix10.34%Insider OwnershipCompanyInsider OwnershipADXNAddex Therapeutics15.00%ATNMActinium Pharmaceuticals0.60%BGMBGM Group58.66%TAOXSynaptogenix2.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableADXNAddex Therapeutics301.23 million1.05 millionNot OptionableATNMActinium Pharmaceuticals3031.38 million29.32 millionOptionableBGMBGM Group29897.22 million40.19 millionN/ATAOXSynaptogenix47.47 million7.27 millionN/AADXN, ATNM, TAOX, and BGM HeadlinesRecent News About These CompaniesTAO Synergies Appoints Bittensor Investor and Author Mark Jeffrey as AdvisorJuly 8, 2026 | prnewswire.comTAO Synergies Set to Join the Russell Microcap® Index as a Leading Public Gateway to Decentralized AIJune 16, 2026 | prnewswire.comTAO Synergies and Yuma Asset Management to Host Livestream on X: Bittensor (TAO) and DeAI InnovationNovember 18, 2025 | prnewswire.comTradr Set to Debut ETFs Targeting Bloom Energy, Celestica, Nano Nuclear and SynopsysNovember 11, 2025 | prnewswire.comTAO Synergies Announces Initial $750,000 Investment in Yuma Asset Management's Subnet FundsNovember 4, 2025 | prnewswire.comTAO Synergies Raises Bittensor (TAO) Holdings to over 54,000 Tokens, Largest Publicly Traded Holder of Top Decentralized AI CryptocurrencyOctober 20, 2025 | prnewswire.comTAO Synergies Announces $11 Million Private PlacementOctober 13, 2025 | prnewswire.comTAO Synergies Launches "The TAO Daily," the Premier Media Platform for All Things Bittensor (TAO)September 22, 2025 | prnewswire.comTAO Synergies Digital Assets Advisor James Altucher Speaks at Google's Planet Scale Consumer AI EventSeptember 8, 2025 | prnewswire.comTAO Synergies (Formerly Synaptogenix) Begins Trading Under New Nasdaq Stock Symbol "TAOX" Effective at Market Open TodayJuly 1, 2025 | prnewswire.comSynaptogenix Announces Name Change to TAO Synergies and New Ticker Symbol "TAOX" for Alignment with AI-Focused Crypto Treasury StrategyJune 26, 2025 | prnewswire.comSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KXAN AustinJune 26, 2025 | kxan.comKSynaptogenix begins TAO acquisition as part of crypto treasury strategyJune 26, 2025 | uk.investing.comSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through Staking - KTLAJune 26, 2025 | ktla.comKSynaptogenix Announces Initial TAO Acquisition under Crypto Treasury Strategy, Appoints BitGo as Custodian, and Commences Yield Generation Through StakingJune 24, 2025 | prnewswire.comSynaptogenix Unveils TAO-Focused Crypto Treasury PlanJune 10, 2025 | livebitcoinnews.comLSynaptogenix Appoints Crypto Expert to Lead Digital Asset Treasury Strategy Focused Exclusively on Top-Valued AI TokenJune 9, 2025 | prnewswire.comSynaptogenix Inc Ordinary SharesJanuary 3, 2025 | morningstar.comMSynaptogenix Board of Directors Forms Special Committee to Explore Value Creation Opportunities Utilizing Balance Sheet StrengthDecember 20, 2024 | prnewswire.comSynaptogenix (NASDAQ:SNPX) Stock Quotes, Forecast and News SummaryOctober 7, 2024 | benzinga.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeADXN, ATNM, TAOX, and BGM Company DescriptionsAddex Therapeutics NASDAQ:ADXN$5.86 -0.03 (-0.42%) Closing price 07/24/2026 03:58 PM EasternExtended Trading$5.86 0.00 (0.00%) As of 07/24/2026 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland.Actinium Pharmaceuticals NYSE:ATNM$0.86 -0.03 (-3.48%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.86 0.00 (-0.47%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.BGM Group NASDAQ:BGM$0.29 0.00 (-0.34%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.29 +0.00 (+0.79%) As of 07/24/2026 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.Synaptogenix NASDAQ:TAOX$3.29 -0.38 (-10.35%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$3.38 +0.09 (+2.74%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Synaptogenix, Inc. operates as a biopharmaceutical company with product candidates in pre-clinical and clinical development. It focuses on developing a product platform based upon a drug candidate called Bryostatin-1 for the treatment of Alzheimer's disease. The company is also evaluating therapeutic applications of bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as fragile X syndrome, multiple sclerosis, and Niemann-pick type C disease. Synaptogenix, Inc. has licensing agreements with Stanford University; Icahn School of Medicine at Mount Sinai; and The Board of Trustees of the Leland Stanford Junior University. The company was incorporated in 2012 and is headquartered in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Plugging In: How Kinder Morgan Powers Up Profits TSMC’s Price Hikes Could Show Which AI Chip Stocks Have Real Pricing Power Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
